- Q2e: 21% ARR growth and adj. EBITDA of DKK 1.1m - '24e likely to be even more back-end loaded vs.
- Rec. PTP 7% below ABGSCe - CEPS est. +2.7-0.6% for '25-26e due to projects - Share trading at a ~3...
Cibus posted Q2 results largely in line with expectations.
- 10% beat on EBITDA vs cons - Strong growth in Technology, but continued weakness in Genetics - Est...
Consti reports its Q2 results on Friday 19th of July.
- EBIT SEK 131m (-11% vs. ABGSCe, -4% vs. FactSet cons) - We expect consensus EBIT to come down by 2...
Redeye updates its estimates and valuation following Serstech's Q1 2024 report.
- Beat on Q2 sales (+3%) and EBITDA (+24%) vs ABGSCe - EBITDA up 2% for '24e and 1% for '25e - Our c...
- Order intake growth driven by sports & outdoor clients - We raise '24e-'26e sales by 2-1% and EBIT...
Redeye updates its estimates for Ependion following the Q2 2024 report, which showed stronger sales ...
AlzeCure Pharma fortsätter alltjämt att generera data för sina projekt har bland annat presenterat n...
Redeye comments on the latest readout from the trial of tasquinimod in multiple myeloma.
Redeye will likely increase its Base Case and forecasts following a strong Q2 report, with solid imp...
Redeye lowered its Base Case and forecasts somewhat following a Q2 report on the somewhat soft side,...
- Q2 in line with ABGSCe but softer outlook for Q3 - We cut adj.
